Karen Swenor
Family · Marquette, MINPI 1871716902
Payments from drug & device makers
Across 220 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$968
- Lilly USA, LLC$333
- Amgen$333
- Lundbeck LLC$256
- Boehringer Ingelheim$253
- Novo Nordisk$235
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,87999%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 57 | $968 |
| Lilly USA, LLC | 21 | $333 |
| Amgen | 18 | $333 |
| Lundbeck LLC | 16 | $256 |
| Boehringer Ingelheim | 13 | $253 |
| Novo Nordisk | 9 | $235 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $182 |
| Johnson & Johnson | 15 | $175 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $168 |
| GSK | 9 | $163 |
| Axsome Therapeutics, Inc. | 8 | $150 |
| Smith+Nephew | 3 | $122 |
| Dexcom, Inc. | 5 | $82 |
| Teva Pharmaceuticals USA, Inc. | 4 | $72 |
| Pfizer | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Bayer | 4 | $58 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Abbott | 2 | $37 |
| Alkermes, Inc. | 2 | $35 |
| Corcept Therapeutics | 1 | $24 |
| Organogenesis Inc. | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,898 in reported general payments places this provider in the 90th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $98,436 |
| EliquisApixaban | 62 | $61,540 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $57,692 |
| RexultiBrexpiprazole | 30 | $42,023 |
| XareltoRivaroxaban | 49 | $37,433 |
| MounjaroTirzepatide | 35 | $36,334 |
| VraylarCariprazine Hcl | 23 | $32,443 |
| JanuviaSitagliptin Phosphate | 21 | $18,585 |
| EntrestoSacubitril/Valsartan | 17 | $16,806 |
| Humalog Kwikpen U-100Insulin Lispro | 32 | $13,918 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $13,647 |
| LinzessLinaclotide | 15 | $11,090 |
| TrintellixVortioxetine Hydrobromide | 19 | $8,956 |
| JardianceEmpagliflozin | 14 | $8,643 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 61 | $7,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $235 | $98,43667 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $163 | $71,33885 claims |
| PfizerEliquis | $70 | $61,54062 claims |
| AbbVieVraylar, Linzess, Synthroid | $968 | $44,87959 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $58 | $42,02330 claims |
| Johnson & JohnsonXarelto | $175 | $37,43349 claims |
| Lilly USA, LLCMounjaro | $333 | $36,33435 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $253 | $14,82426 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $168 | $8,95619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,657 family providers in Michigan.
Other family in Marquette
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
- Brent MillerFremont$66K
- Rachael CompeauFlint$62K
- David KocendaLapeer$49K
- Tracy RobertsonBay City$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.